Acadia Pharmaceuticals Q3 net income falls 25% to $53.52 million
ACAD•Acadia Pharmaceuticals’ third-quarter 2026 net income fell 25% year over year to $53.52 million, while revenue rose 23% to $342.29 million. The company lowered 2026 research and development expense guidance to $325 million–$340 million.
1. Quarterly results and outlook
Third-quarter 2026 research and development expenses fell 13% to $76.28 million, and the company lowered its 2026 guidance for those expenses to $325 million–$340 million. DAYBU launched in Germany in early October after European Commission approval for treating Rett syndrome. Two Phase 2 readouts are expected in 2027: ACP-211 in major depressive disorder and remlifanserin in Lewy body dementia psychosis.
